A new approach on valproic acid induced hepatotoxicity: Involvement of lysosomal membrane leakiness and cellular proteolysis

Toxicology in Vitro

Volumn 26, Issue 4, 2012, Pages 545-551

  Pourahmad, Jalal ^a   Eskandari, Mohammad Reza ^b   Kaghazi, Amineh ^a   Shaki, Fatemeh ^a   Shahraki, Jafar ^a   Fard, Javad Khalili ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cellular proteolysis; Lysosomes; Mitochondrial lysosomal cross talk; Oxidative stress; Rat hepatocytes; Valproic acid

Indexed keywords

3 METHYLADENINE; 4 METHYLPYRAZOLE; ACRIDINE ORANGE; ALPHA TOCOPHEROL SUCCINATE; BUTYLCRESOL; CARNITINE; CHLOROQUINE; CYTOCHROME P450 2E1; DIPHENYLIODONIUM SALT; FLUORESCENT DYE; GLUTATHIONE; MANNITOL; METHYLAMINE; MONENSIN; PHTHALALDEHYDE; RHODAMINE 123; SUCCIMER; TRIFLUOPERAZINE; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; INCUBATION TIME; LIVER CELL; LIVER TOXICITY; LYSOSOME; MALE; MEMBRANE DAMAGE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOLECULAR INTERACTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEGRADATION; RAT;

ANIMALS; ANTICONVULSANTS; ANTIOXIDANTS; CELLS, CULTURED; CYTOCHROME P-450 CYP2E1; DRUG-INDUCED LIVER INJURY; ENZYME INHIBITORS; GLUTATHIONE; HEPATOCYTES; LYSOSOMES; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; PROTEOLYSIS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; VALPROIC ACID;

RATTUS;

EID: 84859764210     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2012.01.020     Document Type: Article

References (46)

1. Andersson B.S., Aw T.Y., Jones D.P. Mitochondrial transmembrane potential and pH gradient during anoxia. Am. J. Physiol. 1987, 252:C349-C355.
2. Björnsson E., Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis. 2006, 38:33-38.
3. Boelsterli U. Xenobiotic-induced oxidative stress: cell injury, signaling, and gene regulation. Mechanistic Toxicology: The Molecular Basis of How Chemicals Disrupt Biological Targets 2007, 117-175. CRC Press, Taylor & Francis Group, Boca Raton.
4. Bond D.J., Lam R.W., Yatham L.N. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J. Affect. Disord. 2010, 124:228-234.
5. Buchi K.N., Gray P.D., Rollins D.E., Tolman K.G. Protection against sodium valproate injury in isolated hepatocytes by alpha-tocopherol and N,N'-diphenyl-p-phenylenediamine. J. Clin. Pharmacol. 1984, 24:148-154.
6. Chang T.K., Abbott F.S. Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug Metab. Rev. 2006, 38:627-639.
7. Defoort E.N., Kim P.M., Winn L.M. Valproic acid increases conservative homologous recombination frequency and reactive oxygen species formation: a potential mechanism for valproic acid-induced neural tube defects. Mol. Pharmacol. 2006, 69:1304-1310.
8. Fu J., Shao C.J., Chen F.R., Ng H.K., Chen Z.P. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol. 2010, 12:328-340.
9. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. 1995, 67:101-154.
10. Galati G., Teng S., Moridani M.Y., Chan T.S., O'Brien P.J. Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug Metabol. Drug Interact. 2000, 17:311-349.
11. Gerber N., Dickinson R.G., Harland R.C., Lynn R.K., Houghton D., Antonias J.I., Schimschock J.C. Reye-like syndrome associated with valproic acid therapy. J. Pediatr. 1979, 95:142-144.
12. Ghozzi H., Hakim A., Sahnoun Z., Ben Mahmoud L., Atheymen R., Hammami S., Zeghal K. Relationship between plasma concentrations of valproic acid and hepatotoxicity in patients receiving high doses. Rev. Neurol. (Paris) 2011.
13. Hissin J., Hilf R. A fluorometric method for determination of oxidised and reduced glutathion in tissues. Anal Biochem. 1976, 74:214-226.
14. Ishikura H., Matsuo N., Matsubara M., Ishihara T., Takeyama N., Tanaka T. Valproic acid overdose and l-carnitine therapy. J. Anal. Toxicol. 1996, 20:55-58.
15. Johannessen S.I., Landmark C.J. Antiepileptic drug interactions-principles and clinical implications. Curr. Neuropharmacol. 2010, 8:254-267.
16. Jurima-Romet M., Abbott F.S., Tang W., Huang H.S., Whitehouse L.W. Cytotoxicity of unsaturated metabolites of valproic acid and protection by vitamins C and E in glutathione-depleted rat hepatocytes. Toxicology 1996, 112:69-85.
17. Khan S., O'Brien P.J. 1-Bromoalkanes as new potent nontoxic glutathione depletors in isolated rat hepatocytes. Biochem. Biophys. Res. Commun. 1991, 179:436-441.
18. Khojasteh S.C., Prabhu S., Kenny J.R., Halladay J.S., Lu A.Y. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur. J. Drug Metab. Pharmacokinet. 2011, 36:1-16.
19. Kiang T.K., Teng X.W., Karagiozov S., Surendradoss J., Chang T.K., Abbott F.S. Role of oxidative metabolism in the effect of valproic acid on markers of cell viability, necrosis, and oxidative stress in sandwich-cultured rat hepatocytes. Toxicol. Sci. 2010, 118:501-509.
20. Kiang T.K., Teng X.W., Surendradoss J., Karagiozov S., Abbott F.S., Chang T.K. Glutathione depletion by valproic acid in sandwich-cultured rat hepatocytes: role of biotransformation and temporal relationship with onset of toxicity. Toxicol. Appl. Pharmacol. 2011, 252:318-324.
21. Kingsley E., Gray P., Tolman K.G., Tweedale R. The toxicity of metabolites of sodium valproate in cultured hepatocytes. J Clin Pharmacol. 1983, 23:178-185.
22. Krähenbühl S., Mang G., Kupferschmidt H., Meier P.J., Krause M. Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity. Gut 1995, 37:140-143.
23. Luef G., Rauchenzauner M., Waldmann M., Sturm W., Sandhofer A., Seppi K. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res. 2009, 86:42-47.
24. Luef G.J., Waldmann M., Sturm W., Naser A., Trinka E., Unterberger I., Bauer G., Lechleitner M. Valproate therapy and nonalcoholic fatty liver disease. Ann. Neurol. 2004, 55:729-732.
25. Meister A. Selective modification of glutathione metabolism. Science 1983, 220:427-477.
26. Moldeus P., Hogberg J., Orrenius S. Isolation and use of liver cells. Meth. Enzymol. 1978, 52:60-71.
27. Na L., Wartenberg M., Nau H., Hescheler J., Sauer H. Anticonvulsant valproic acid inhibits cardiomyocyte differentiation of embryonic stem cells by increasing intracellular levels of reactive oxygen species. Birth Defects Res. A Clin. Mol. Teratol. 2003, 67:174-180.
28. Novak R.F., Kharasch E.D., Wendel N.K. Nitrofurantoin stimulated proteolysis in human erythrocytes: a novel index of toxic insult by nitroaromatics. J. Pharmacol. Exp. Ther. 1988, 247:439-444.
29. Pessayre D., Mansouri A., Haouzi D., Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol. Toxicol. 1999, 15:367-373.
30. Ponchaut S., Veitch K. Valproate and mitochondria. Biochem. Pharmacol. 1993, 46:199-204.
31. Pourahmad J., Eskandari M.R., Daraei B. A comparison of hepatocyte cytotoxic mechanisms for thallium (I) and thallium (III). Environ. Toxicol. 2010, 25:456-467.
32. Pourahmad J., Eskandari M.R., Nosrati M., Kobarfard F., Khajeamiri A.R. Involvement of mitochondrial/lysosomal toxic cross-talk in ecstasy induced liver toxicity under hyperthermic condition. Eur. J. Pharmacol. 2010, 643:162-169.
33. Pourahmad J., Hosseini M.J., Eskandari M.R., Shekarabi S.M., Daraei B. Mitochondrial/lysosomal toxic cross-talk plays a key role in cisplatin nephrotoxicity. Xenobiotica 2010, 40:763-771.
34. 2+. Toxicology 2000, 143:263-273.
35. 2+. Free Radic. Biol. Med. 2001, 30:89-97.
36. Sato K., Ueda Y., Ueno K., Okamoto K., Iizuka H., Katsuda S. Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. Virchows Arch. 2005, 447:996-999.
37. Seglen P.O., Gordon P.B. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc. Natl. Acad. Sci. USA 1982, 79:1889-1892.
38. Silberstein S.D. Valproic acid: clinical efficacy and use in other neurological disorders. Antiepileptic Drugs 2002, 818-827. Lippincott, Williams & Wilkins, Philadelphia. R.H. Levy, R.H. Mattson, B.S. Meldrum (Eds.).
39. Silva M.F., Aires C.C., Luis P.B., Ruiter J.P., Ijlst L., Duran M., Wanders R.J., Tavares de Almeida I. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J. Inherit. Metab. Dis. 2008, 31:205-216.
40. Tong V., Chang T.K., Chen J., Abbott F.S. The effect of valproic acid on hepatic and plasma levels of 15-F(2t)-isoprostane in rats. Free Radic. Biol. Med. 2003, 34:1435-1446.
41. Tong V., Teng X.W., Chang T.K.H., Abbott F.S. Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol. Sci. 2005, 86:427-435.
42. Tong V., Teng X.W., Chang T.K.H., Abbott F.S. Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol. Sci. 2005, 86:436-443.
43. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell. Biol. 2007, 39:44-84.
44. Verrotti A., Di Marco G., La Torre R., Pelliccia P., Chiarelli F. Nonalcoholic fatty liver disease during valproate therapy. Eur. J. Pediatr. 2009, 168:1391-1394.
45. Zhang B., Wang X., Nazarali A.J. Ascorbic acid reverses valproic acid-induced inhibition of hoxa2 and maintains glutathione homeostasis in mouse embryos in culture. Cell. Mol. Neurobiol. 2010, 30:137-148.
46. Zimmerman H.J., Ishak K.G. Valproate-induced hepatic injury: analysis of 23 fatal cases. Hepatology 1982, 2:591-597.